Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient

NCT01858207 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE: Transcatheter Arterial Chemoembolization
PROCEDURE: Radiofrequency ablation
DRUG: Doxorubicin

Sponsor

Shi-Ming Lin